{
    "info": {
        "nct_id": "NCT05878184",
        "official_title": "A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)",
        "inclusion_criteria": "* Male or female subjects aged 18-80 years at the time of signing informed consent.\n* Diagnosis of NHL (WHO 2016 criteria) or CLL (iwCLL criteria), including:\n* Large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise - - specified (including DLBCL arising from indolent lymphoma), primary mediastinal large -- - B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma grade 3B\n* Follicular lymphoma (dose escalation only except for follicular lymphoma grade 3B)\n* Marginal zone lymphoma (dose escalation only)\n* Mantle cell lymphoma (dose escalation only)\n* CLL or SLL\n* Relapsed/refractory disease after at least 2 prior systemic regimens per standard of care or after autologous stem cell transplant\n* ECOG performance status of 0 or 1.\n* At least one measurable lesion per Lugano Classification (NHL); CLL subjects must meet iwCLL treatment criteria\n* Life expectancy ≥12 weeks\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
        "exclusion_criteria": "* Prior anti-CD19 therapy including CD19-directed CAR T treatment or other CD19-directed antibody or cell therapy (e.g., NK cell). (Part 2 dose expansion only - prior approved CD19-directed CAR T therapy required)\n* History of primary central nervous system (CNS) lymphoma or presence of CNS metastases\n* Systemic anticancer therapy (including platinum-based chemotherapies and I/O therapies) or radiotherapy within 14 days of SC291 (28 days for biologics)\n* Autologous HSCT within 6 weeks of treatment with SC291 (or allogeneic HSCT at any time).\n* Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >20 mg/day prednisone or equivalent).\n* History or presence of cardiac or CNS disorders as defined in the protocol",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Relapsed/refractory disease after at least 2 prior systemic regimens per standard of care or after autologous stem cell transplant",
            "criterions": [
                {
                    "exact_snippets": "Relapsed/refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 2 prior systemic regimens per standard of care",
                    "criterion": "number of prior systemic regimens",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "after autologous stem cell transplant",
                    "criterion": "history of autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Mantle cell lymphoma (dose escalation only)",
            "criterions": [
                {
                    "exact_snippets": "Mantle cell lymphoma (dose escalation only)",
                    "criterion": "mantle cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cohort",
                            "expected_value": "dose escalation only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of NHL (WHO 2016 criteria) or CLL (iwCLL criteria), including:",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of NHL (WHO 2016 criteria)",
                    "criterion": "non-Hodgkin lymphoma (NHL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "WHO 2016 criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... CLL (iwCLL criteria)",
                    "criterion": "chronic lymphocytic leukemia (CLL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "iwCLL criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 80 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 80 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 80,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one measurable lesion per Lugano Classification (NHL); CLL subjects must meet iwCLL treatment criteria",
            "criterions": [
                {
                    "exact_snippets": "At least one measurable lesion per Lugano Classification (NHL)",
                    "criterion": "measurable lesion (per Lugano Classification)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CLL subjects must meet iwCLL treatment criteria",
                    "criterion": "iwCLL treatment criteria (for CLL subjects)",
                    "requirements": [
                        {
                            "requirement_type": "meets iwCLL treatment criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Marginal zone lymphoma (dose escalation only)",
            "criterions": [
                {
                    "exact_snippets": "Marginal zone lymphoma (dose escalation only)",
                    "criterion": "marginal zone lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "trial phase restriction",
                            "expected_value": "dose escalation only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CLL or SLL",
            "criterions": [
                {
                    "exact_snippets": "CLL or SLL",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "CLL",
                                "SLL"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise - - specified (including DLBCL arising from indolent lymphoma), primary mediastinal large -- - B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma grade 3B",
            "criterions": [
                {
                    "exact_snippets": "Large B-cell lymphoma",
                    "criterion": "Large B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diffuse large B-cell lymphoma (DLBCL) not otherwise - - specified (including DLBCL arising from indolent lymphoma)",
                    "criterion": "diffuse large B-cell lymphoma (DLBCL)",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "not otherwise specified"
                        },
                        {
                            "requirement_type": "origin",
                            "expected_value": [
                                "arising from indolent lymphoma",
                                "not arising from indolent lymphoma"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "primary mediastinal large -- - B-cell lymphoma",
                    "criterion": "primary mediastinal large B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "high grade B-cell lymphoma",
                    "criterion": "high grade B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "follicular lymphoma grade 3B",
                    "criterion": "follicular lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "3B"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Follicular lymphoma (dose escalation only except for follicular lymphoma grade 3B)",
            "criterions": [
                {
                    "exact_snippets": "Follicular lymphoma (dose escalation only except for follicular lymphoma grade 3B)",
                    "criterion": "follicular lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "trial phase eligibility",
                            "expected_value": "dose escalation only"
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "follicular lymphoma grade 3B"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female subjects aged 18-80 years at the time of signing informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Male or female subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "aged 18-80 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 80,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at the time of signing informed consent",
                    "criterion": "age at time of consent",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "at time of signing informed consent"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Autologous HSCT within 6 weeks of treatment with SC291 (or allogeneic HSCT at any time).",
            "criterions": [
                {
                    "exact_snippets": "Autologous HSCT within 6 weeks of treatment with SC291",
                    "criterion": "autologous HSCT",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation to treatment",
                            "expected_value": "prior to SC291 treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "allogeneic HSCT at any time",
                    "criterion": "allogeneic HSCT",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or presence of cardiac or CNS disorders as defined in the protocol",
            "criterions": [
                {
                    "exact_snippets": "History or presence of cardiac ... disorders",
                    "criterion": "cardiac disorders",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History or presence of ... CNS disorders",
                    "criterion": "CNS disorders",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic anticancer therapy (including platinum-based chemotherapies and I/O therapies) or radiotherapy within 14 days of SC291 (28 days for biologics)",
            "criterions": [
                {
                    "exact_snippets": "Systemic anticancer therapy (including platinum-based chemotherapies and I/O therapies) or radiotherapy within 14 days of SC291 (28 days for biologics)",
                    "criterion": "systemic anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Systemic anticancer therapy (including platinum-based chemotherapies and I/O therapies) or radiotherapy within 14 days of SC291 (28 days for biologics)",
                    "criterion": "biologic anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Systemic anticancer therapy (including platinum-based chemotherapies and I/O therapies) or radiotherapy within 14 days of SC291 (28 days for biologics)",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of primary central nervous system (CNS) lymphoma or presence of CNS metastases",
            "criterions": [
                {
                    "exact_snippets": "History of primary central nervous system (CNS) lymphoma",
                    "criterion": "primary central nervous system (CNS) lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-CD19 therapy including CD19-directed CAR T treatment or other CD19-directed antibody or cell therapy (e.g., NK cell). (Part 2 dose expansion only - prior approved CD19-directed CAR T therapy required)",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-CD19 therapy including CD19-directed CAR T treatment or other CD19-directed antibody or cell therapy (e.g., NK cell)",
                    "criterion": "prior anti-CD19 therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Part 2 dose expansion only - prior approved CD19-directed CAR T therapy required",
                    "criterion": "prior approved CD19-directed CAR T therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "study part",
                            "expected_value": "Part 2 dose expansion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >20 mg/day prednisone or equivalent).",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other diseases requiring immunosuppressive therapy",
                    "criterion": "diseases requiring immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for immunosuppressive therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diseases requiring ... corticosteroid therapy (defined as >20 mg/day prednisone or equivalent)",
                    "criterion": "diseases requiring corticosteroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for corticosteroid therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "corticosteroid dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "mg/day prednisone or equivalent"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}